Citius Oncology, Inc. (CTOR NASDAQ) stock market data APIs
$5.1779
-0.18(-3.5%)
as of July 2, 2025
Try our APIs with
free plan!
Citius Oncology, Inc. Financial Data Overview
Price chart is built with
Anychart
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Prev. Close
5.1779
Open
4.9953
High
5.4397
Low
4.7628
52 wk Range
0.551-40.5
Market Cap
105 M
Shares Outstanding
71 552 K
EPS
-0.11
Beta
-0.063
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Citius Oncology, Inc. data using free add-ons & libraries
Get Citius Oncology, Inc. Fundamental Data
Citius Oncology, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-15
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Citius Oncology, Inc. News
New
US High Growth Tech Stocks with Promising Potential
The United States market has shown robust performance recently, climbing 3.4% in the last 7 days and rising 14% over the past year, with earnings forecast to grow by 15% annually. In this thriving env...
Catalyst Watch: Jobs Report, Tesla deliveries, Constellation Brands earnings, and Circle ratings
[Trading charts background] da-kuk/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that...
VOR Skyrockets On Ex-China Rights To Autoimmune Drug, ADIL To Face FDA On Jul.29, PSTV Jumps 14%
(RTTNews) - What's driving the momentum in the following stocks? Vor Bio, Inc. (VOR) has secured ex-Greater China rights from RemeGen Co., Ltd. to develop and commercialize Telitacicept, a novel dual...
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.08%
Investing.com – U.S. stocks were mixed after the close on Friday, as gains in the Oil & Gas, Consumer Goods and Telecoms sectors led shares higher while losses in the Basic Materials, Technology and...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
